Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note issued on Wednesday. The brokerage set a “sell” rating on the stock.

MBRX has been the topic of several other research reports. Roth Mkm reaffirmed a “buy” rating and set a $40.00 target price on shares of Moleculin Biotech in a research report on Friday, April 12th. Maxim Group dropped their target price on Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, March 26th.

Moleculin Biotech Stock Performance

MBRX opened at $3.42 on Wednesday. The stock’s fifty day moving average is $4.14 and its two-hundred day moving average is $5.99. Moleculin Biotech has a 52 week low of $3.21 and a 52 week high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings data on Friday, May 10th. The company reported ($2.02) EPS for the quarter, topping the consensus estimate of ($3.59) by $1.57. On average, research analysts anticipate that Moleculin Biotech will post -8.79 EPS for the current year.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Armistice Capital LLC acquired a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned approximately 9.60% of Moleculin Biotech at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.